Pharmaceutical Technology6 天
Anifrolumab by AstraZeneca for Vitiligo: Likelihood of Approval
Anifrolumab is under clinical development by AstraZeneca and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs for Vitiligo have a 42% phase transition success rate (PTSR) ...
Pharmaceutical Technology6 天
Anifrolumab by AstraZeneca for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase III drugs for Systemic Sclerosis (Scleroderma) ...
pharmaphorum5 天
AZ fleshes out positive trial of revitalised lupus drug anifrolumab
After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...
pharmaphorum4 天
AZ's lupus drug Saphnelo cleared in EU, challenging GSK's Benlysta
Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...